In order to further validate the antitumor potential of PRMT5 deficiency in cervical cancer treatment, we selected the PRMT5 inhibitor EPZ015666 to evaluate its possible therapeutic effects (Figure S2A). The gene discussed is PRMT5; the disease is cervical cancer.